Predictive value of HLA-G and HLA-E in the prognosis of colorectal cancer patients

Cellular Immunology

Volumn 293, Issue 1, 2015, Pages 10-16

  Guo, Zhang Yan ^a   Lv, Yong Gang ^b   Wang, Lei ^a   Shi, Sheng Jia ^a   Yang, Fan ^b   Zheng, Guo Xu ^a   Wen, Wei Hong ^a   Yang, An Gang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Colorectal carcinoma; HLA E; HLA G; Prognosis

Indexed keywords

HLA E ANTIGEN; HLA G ANTIGEN; HLA ANTIGEN CLASS 1; HLA-E ANTIGEN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; COLORECTAL CANCER; COLORECTAL CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; ADENOCARCINOMA; AGED; CANCER GRADING; CANCER STAGING; COLORECTAL TUMOR; GENE EXPRESSION; GENETICS; IMMUNOLOGY; LYMPH NODE METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA-G ANTIGENS; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84911924555     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2014.10.003     Document Type: Article

References (33)

1. Carosella E.D., Moreau P., Le Maoult J., Le Discorde M., Dausset J., Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv. Immunol. 2003, 81:199-252.
2. Yang Y., Chu W., Geraghty D.E., Hunt J.S. Expression of HLA-G in human mononuclear phagocytes and selective induction by IFN-gamma. J. Immunol. 1996, 156(11):4224-4231.
3. Fujii T., Ishitani A., Geraghty D.E. A soluble form of the HLA-G antigen is encoded by a messenger ribonucleic acid containing intron 4. J. Immunol. 1994, 153(12):5516-5524.
4. O'Callaghan C.A.J.I. Bell. Structure and function of the human MHC class Ib molecules HLA-E, HLA-F and HLA-G. Immunol. Rev. 1998, 163:129-138.
5. Pistoia V., Morandi F., Wang X., Ferrone S. Soluble HLA-G: Are they clinically relevant?. Semin. Cancer Biol. 2007, 17(6):469-479.
6. Faure M., Long E.O. KIR2DL4 (CD158d), an NK cell-activating receptor with inhibitory potential. J. Immunol. 2002, 168(12):6208-6214.
7. Braud V., Jones E.Y., McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur. J. Immunol. 1997, 27(5):1164-1169.
8. Braud V.M., Allan D.S., O'Callaghan C.A., et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998, 391(6669):795-799.
9. Moretta L., Romagnani C., Pietra G., Moretta A., Mingari M.C. NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol. 2003, 24(3):136-143.
10. Paul P., Rouas-Freiss N., Khalil-Daher I., et al. HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc. Natl. Acad. Sci. USA 1998, 95(8):4510-4515.
11. Bukur J., Malenica B., Huber C., Seliger B. Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. Hum. Immunol. 2003, 64(11):1081-1092.
12. Rouas-Freiss N., Moreau P., Menier C., Carosella E.D. HLA-G in cancer: a way to turn off the immune system. Semin. Cancer Biol. 2003, 13(5):325-336.
13. Davidson B., Elstrand M.B., McMaster M.T., et al. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma. Gynecol. Oncol. 2005, 96(1):42-47.
14. Yie S.M., Hu Z. Human leukocyte antigen-G (HLA-G) as a marker for diagnosis, prognosis and tumor immune escape in human malignancies. Histol. Histopathol. 2011, 26(3):409-420.
15. Fukushima Y., Oshika Y., Nakamura M., et al. Increased expression of human histocompatibility leukocyte antigen-G in colorectal cancer cells. Int. J. Mol. Med. 1998, 2(3):349-351.
16. Ye S.R., Yang H., Li K., Dong D.D., Lin X.M., Yie S.M. Human leukocyte antigen G expression: as a significant prognostic indicator for patients with colorectal cancer. Mod. Pathol. 2007, 20(3):375-383.
17. Zhu C.B., Wang C.X., Zhang X., Zhang J., Li W. Serum sHLA-G levels: a useful indicator in distinguishing colorectal cancer from benign colorectal diseases. Int. J. Cancer 2011, 128(3):617-622.
18. Leelawat K., Engprasert S., Pongchai-rerk U., Tuchinda S., Suthipintawong C., Leardkamolkarn V. No expression of human leukocyte antigen G (HLA-G) in colorectal cancer cells. J. Med. Assoc. Thai. 2004, 87(7):816-818.
19. Levy E.M., Bianchini M., Von Euw E.M., et al. Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer. Int. J. Oncol. 2008, 32(3):633-641.
20. Zhen Z.J., Ling J.Y., Cai Y., Luo W.B., He Y.J. Impact of HLA-E gene polymorphism on HLA-E expression in tumor cells and prognosis in patients with stage III colorectal cancer. Med. Oncol. 2013, 30(1):482.
21. Benevolo M., Mottolese M., Tremante E., et al. High expression of HLA-E in colorectal carcinoma is associated with a favorable prognosis. J. Transl. Med. 2011, 9:184.
22. de Kruijf E.M., Sajet A., van Nes J.G., et al. HLA-E and HLA-G expression in classical HLA class I-negative tumors is of prognostic value for clinical outcome of early breast cancer patients. J. Immunol. 2010, 185(12):7452-7459.
23. Lampen M.H., van Hall T. Strategies to counteract MHC-I defects in tumors. Curr. Opin. Immunol. 2011, 23(2):293-298.
24. Marin R., Ruiz-Cabello F., Pedrinaci S., et al. Analysis of HLA-E expression in human tumors. Immunogenetics 2003, 54(11):767-775.
25. Carosella E.D., Moreau P., Lemaoult J., Rouas-Freiss N. HLA-G: from biology to clinical benefits. Trends Immunol. 2008, 29(3):125-132.
26. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D., Lin X.M. Expression of human leukocyte antigen G (HLA-G) correlates with poor prognosis in gastric carcinoma. Ann. Surg. Oncol. 2007, 14(10):2721-2729.
27. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D., Lin X.M. Expression of HLA-G is associated with prognosis in esophageal squamous cell carcinoma. Am. J. Clin. Pathol. 2007, 128(6):1002-1009.
28. Yie S.M., Yang H., Ye S.R., Li K., Dong D.D., Lin X.M. Expression of human leucocyte antigen G (HLA-G) is associated with prognosis in non-small cell lung cancer. Lung Cancer 2007, 58(2):267-274.
29. Wischhusen J., Friese M.A., Mittelbronn M., Meyermann R., Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J. Neuropathol. Exp. Neurol. 2005, 64(6):523-528.
30. Derre L., Corvaisier M., Charreau B., et al. Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells. J. Immunol. 2006, 177(5):3100-3107.
31. Evans C., Dalgleish A.G., Kumar D. Review article: immune suppression and colorectal cancer. Aliment. Pharmacol. Ther. 2006, 24(8):1163-1177.
32. Hofmeister V., Weiss E.H. HLA-G modulates immune responses by diverse receptor interactions. Semin. Cancer Biol. 2003, 13(5):317-323.
33. Bossard C., Bezieau S., Matysiak-Budnik T., et al. HLA-E/beta2 microglobulin overexpression in colorectal cancer is associated with recruitment of inhibitory immune cells and tumor progression. Int. J. Cancer 2012, 131(4):855-863.